Anika Therapeutics, Inc (ANIK)

Etorro trading 970x250
Anika Therapeutics, Inc (ANIK) Logo

About Anika Therapeutics, Inc

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company’s joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730

Anika Therapeutics, Inc News and around…

Latest news about Anika Therapeutics, Inc (ANIK) common stock and company :

Add Up The Parts: VIOG Could Be Worth $282
14 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Small-Cap 600 Growth ETF (VIOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $282.11 per unit.

Land This Bargain Even Cheaper Than EVP, CFO, Treasurer Levitz Did
14 Dec, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on August 12, Anika Therapeutics Inc.'s EVP, CFO, Treasurer, Michael L..

VIOG's Holdings Could Mean 20% Gain Potential
14 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Small-Cap 600 Growth ETF (VIOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $277.15 per unit.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Dec, 2021 Yahoo! Finance

BEDFORD, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on December 1, 2021, Anika granted non-statutory stock options covering an aggregate of 1,069 shares of common stock (the “Options”) and restricted stock units (the “RSUs”) covering an aggregate of 468 shares of common stock to 1 newly hired non-executive employee. Each grant was made pursuant to the Anika Therapeut

Anika to Participate in Upcoming Investor Conferences
18 Nov, 2021 Yahoo! Finance

BEDFORD, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences: The Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. A pre-recorde

Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021
16 Nov, 2021 FinancialContent

Upgrades According to Maxim Group, the prior rating for VirTra Inc (NASDAQ:VTSI) was changed from Hold to Buy. For the ...

Investors five-year losses grow to 14% as the stock sheds US$91m this past week
13 Nov, 2021 Yahoo! Finance

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Analysts Forecast 10% Upside For SLYV
12 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P 600 Small Cap Value ETF (SLYV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $98.51 per unit.

Anika Therapeutics, inc (ANIK) Q3 2021 Earnings Call Transcript
05 Nov, 2021 FinancialContent

ANIK earnings call for the period ending September 30, 2021.

Anika Therapeutics (ANIK) Tops Q3 Earnings and Revenue Estimates
04 Nov, 2021 Yahoo! Finance

Anika (ANIK) delivered earnings and revenue surprises of 144.44% and 8.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Anika Reports Third Quarter 2021 Financial Results
04 Nov, 2021 Yahoo! Finance

Revenue growth of 25% year-over-yearCompany revises revenue growth outlook for 2021 to 9-11% on COVID Delta headwinds BEDFORD, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Financial Summary Revenue in the third quarter of 2021 was $39.5 million, 25% higher than prior year, compared with $31.

Anika Appoints Sheryl Conley to Board of Directors
01 Nov, 2021 Yahoo! Finance

Appointment brings experienced orthopedic industry commercial leader to Anika’s BoardBEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, mo

Anika Therapeutics (ANIK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
28 Oct, 2021 Yahoo! Finance

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anika to Issue Third Quarter 2021 Financial Results on Thursday, November 4, 2021
18 Oct, 2021 Yahoo! Finance

BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2021 financial results after the close of the market on Thursday, November 4, 2021 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-437-239

Top Buys by Top Brass: EVP, CFO, Treasurer Levitz's $145.8K Bet on ANIK
06 Oct, 2021 FinancialContent

A company's own top management tend to have the best inside view into the business, so when company officers make major buys, investors are wise to take notice. Presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
30 Sep, 2021 FinancialContent

Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion

Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation
14 Sep, 2021 FinancialContent

510(k) clearance expands the capability of Tactoset for augmenting suture anchor fixation

Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
07 Sep, 2021 FinancialContent
Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
01 Sep, 2021 FinancialContent

Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market

Return on Capital Employed Insights for Anika Therapeutics
23 Aug, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Anika Therapeutics (NASDAQ:ANIK) earned $9.18 million, a 629.73% increase ...

Trade Alert: The Executive VP Of Anika Therapeutics, Inc. (NASDAQ:ANIK), Michael Levitz, Has Just Spent US$146k Buying 94% More Shares
15 Aug, 2021 Yahoo! Finance

Potential Anika Therapeutics, Inc. ( NASDAQ:ANIK ) shareholders may wish to note that the Executive VP, Michael Levitz...

Anika Therapeutics, inc (ANIK) Q2 2021 Earnings Call Transcript
06 Aug, 2021 FinancialContent

ANIK earnings call for the period ending June 30, 2021.

Anika Reports Second Quarter 2021 Financial Results
05 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021
19 Jul, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
16 Jul, 2021 FinancialContent

Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE:AA) was changed from Neutral to Buy. In the ...

First Anika WristMotion® Total Wrist Arthroplasty Surgery Performed
01 Jul, 2021 FinancialContent

WristMotion Total Wrist Arthroplasty limited launch initiated

Land This Bargain Even Cheaper Than Director Henneman III Did
14 Jun, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on May 18, Anika Therapeutics Inc.'s Director, John B..

Notable Friday Option Activity: TSLA, VRTX, ANIK
11 Jun, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Tesla Inc (TSLA), where a total of 1.0 million contracts have traded so far, representing approximately 100.5 million underlying shares. That amounts to about 353.9% of TSLA's average daily trading volume over the past month of 28.4 million shares..

Anika Therapeutics, Inc (ANIK) is a NASDAQ Common Stock listed in , ,

970x250